1120 Precision Bio Lilly
BioCentury & Getty Images

Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

With $135M up front, Lilly deal unlocks value from biotech’s ARCUS genome-editing tech

Nov 20, 2020 | 11:35 PM GMT

A deal with Lilly delivering $135 million up front will allow Precision BioSciences to derive immediate value from the in vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of CAR T

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE